HUP0000641A3 - Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them - Google Patents
Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing themInfo
- Publication number
- HUP0000641A3 HUP0000641A3 HU0000641A HUP0000641A HUP0000641A3 HU P0000641 A3 HUP0000641 A3 HU P0000641A3 HU 0000641 A HU0000641 A HU 0000641A HU P0000641 A HUP0000641 A HU P0000641A HU P0000641 A3 HUP0000641 A3 HU P0000641A3
- Authority
- HU
- Hungary
- Prior art keywords
- ortho
- pharmaceutical compositions
- compositions containing
- acid derivatives
- hydroxamic acid
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- -1 aryl hydroxamic Chemical compound 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/06—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73263196A | 1996-10-16 | 1996-10-16 | |
PCT/US1997/018280 WO1998016503A2 (en) | 1996-10-16 | 1997-10-08 | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0000641A2 HUP0000641A2 (hu) | 2000-10-28 |
HUP0000641A3 true HUP0000641A3 (en) | 2001-02-28 |
Family
ID=24944349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000641A HUP0000641A3 (en) | 1996-10-16 | 1997-10-08 | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0938471B1 (xx) |
JP (1) | JP2001504809A (xx) |
KR (1) | KR20000049196A (xx) |
AR (1) | AR009382A1 (xx) |
AT (1) | ATE210637T1 (xx) |
AU (1) | AU731737B2 (xx) |
BR (1) | BR9712525A (xx) |
CA (1) | CA2268894A1 (xx) |
DE (1) | DE69709160T2 (xx) |
DK (1) | DK0938471T3 (xx) |
ES (1) | ES2166102T3 (xx) |
HK (1) | HK1021178A1 (xx) |
HU (1) | HUP0000641A3 (xx) |
IL (1) | IL129147A0 (xx) |
NZ (1) | NZ335028A (xx) |
PT (1) | PT938471E (xx) |
TW (1) | TW410220B (xx) |
WO (1) | WO1998016503A2 (xx) |
ZA (1) | ZA979233B (xx) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1310716A (zh) * | 1998-07-30 | 2001-08-29 | 沃尼尔·朗伯公司 | 作为基质金属蛋白酶抑制剂的三环磺胺化合物及其衍生物 |
AU4229499A (en) | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
AU5647099A (en) * | 1998-09-11 | 2000-04-03 | Shionogi & Co., Ltd. | Remedal or preventive agent for congestive heart failure |
AR035478A1 (es) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
IL144322A0 (en) * | 1999-01-27 | 2002-05-23 | American Cyanamid Co | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid as tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
WO2000056704A1 (en) * | 1999-03-22 | 2000-09-28 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
GB9911073D0 (en) * | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
GB9911071D0 (en) * | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
ATE514674T1 (de) | 1999-11-23 | 2011-07-15 | Methylgene Inc | Inhibitoren für histone-deacetylase |
AR027943A1 (es) * | 2000-02-25 | 2003-04-16 | Wyeth Corp | Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
EP1408986B1 (en) * | 2001-05-08 | 2008-09-24 | Yale University | Proteomimetic compounds and methods |
CA2464727A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US20040029771A1 (en) * | 2002-02-28 | 2004-02-12 | Icagen, Inc. | Methods for treating diseases related to intraocular pressure |
US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
EP1449538A1 (en) * | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
KR100793095B1 (ko) * | 2003-10-01 | 2008-01-10 | 주식회사 프로메디텍 | Bace 저해효능을 가진 신규한 술폰 아미드 유도체 |
US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
UA85405C2 (ru) | 2004-04-07 | 2009-01-26 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Производные 1,1'-(1,2-этиндиил)бис-бензола как ингибиторы ртр-1в |
FR2872159B1 (fr) * | 2004-06-28 | 2007-10-05 | Merck Sante Soc Par Actions Si | Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete |
EP1983971A4 (en) | 2006-01-25 | 2010-11-24 | Synta Pharmaceuticals Corp | SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS |
US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
TWI415827B (zh) | 2006-12-21 | 2013-11-21 | Du Pont | 製備2-胺基-5-氰基苯甲酸衍生物之方法 |
GB0705400D0 (en) * | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
US7850453B2 (en) | 2007-08-08 | 2010-12-14 | Coll Partners Ltd. | Reshapable device for fixation at a dental site |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
KR20140071518A (ko) * | 2009-05-01 | 2014-06-12 | 라퀄리아 파마 인코포레이티드 | Trpm8 길항제로서의 설파모일 벤조산 유도체 |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2962649A1 (fr) | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
US9668844B2 (en) | 2013-11-06 | 2017-06-06 | Colldent Y.A Ltd | Device for fixation at a dental site |
TWI678354B (zh) | 2014-05-29 | 2019-12-01 | 新加坡商艾佛艾姆希農業新加坡有限公司 | 藉空氣氧化製備3-甲基-2-硝基苯甲酸之製程 |
MA41587A (fr) | 2014-12-17 | 2021-04-28 | Pimco 2664 Ltd | N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
WO2017117130A1 (en) | 2015-12-28 | 2017-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
JP2022512584A (ja) | 2018-10-04 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 角皮症を処置するためのegfrインヒビター |
WO2024028654A2 (en) * | 2022-08-05 | 2024-02-08 | The Governing Council Of The University Of Toronto | Histone deacetylase inhibitors and use of the same |
CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[(4-磺胺哌嗪-1-基)甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB2303850B (en) * | 1994-06-22 | 1998-06-10 | British Biotech Pharm | Metalloproteinase inhibitors |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
-
1997
- 1997-10-08 DK DK97946246T patent/DK0938471T3/da active
- 1997-10-08 JP JP51844898A patent/JP2001504809A/ja not_active Ceased
- 1997-10-08 WO PCT/US1997/018280 patent/WO1998016503A2/en not_active Application Discontinuation
- 1997-10-08 EP EP97946246A patent/EP0938471B1/en not_active Expired - Lifetime
- 1997-10-08 DE DE69709160T patent/DE69709160T2/de not_active Expired - Fee Related
- 1997-10-08 AT AT97946246T patent/ATE210637T1/de not_active IP Right Cessation
- 1997-10-08 PT PT97946246T patent/PT938471E/pt unknown
- 1997-10-08 KR KR1019990703294A patent/KR20000049196A/ko not_active Application Discontinuation
- 1997-10-08 ES ES97946246T patent/ES2166102T3/es not_active Expired - Lifetime
- 1997-10-08 NZ NZ335028A patent/NZ335028A/xx unknown
- 1997-10-08 HU HU0000641A patent/HUP0000641A3/hu unknown
- 1997-10-08 CA CA002268894A patent/CA2268894A1/en not_active Abandoned
- 1997-10-08 BR BR9712525-3A patent/BR9712525A/pt not_active Application Discontinuation
- 1997-10-08 AU AU51458/98A patent/AU731737B2/en not_active Ceased
- 1997-10-08 IL IL12914797A patent/IL129147A0/xx unknown
- 1997-10-15 AR ARP970104751A patent/AR009382A1/es not_active Application Discontinuation
- 1997-10-15 ZA ZA979233A patent/ZA979233B/xx unknown
- 1997-10-15 TW TW086114187A patent/TW410220B/zh not_active IP Right Cessation
-
2000
- 2000-01-06 HK HK00100090A patent/HK1021178A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0938471T3 (da) | 2002-01-28 |
KR20000049196A (ko) | 2000-07-25 |
AR009382A1 (es) | 2000-04-12 |
NZ335028A (en) | 2000-09-29 |
ATE210637T1 (de) | 2001-12-15 |
WO1998016503A2 (en) | 1998-04-23 |
DE69709160D1 (de) | 2002-01-24 |
HUP0000641A2 (hu) | 2000-10-28 |
ES2166102T3 (es) | 2002-04-01 |
DE69709160T2 (de) | 2002-08-14 |
WO1998016503A3 (en) | 1998-05-28 |
AU5145898A (en) | 1998-05-11 |
JP2001504809A (ja) | 2001-04-10 |
CA2268894A1 (en) | 1998-04-23 |
ZA979233B (en) | 1999-04-15 |
EP0938471A1 (en) | 1999-09-01 |
IL129147A0 (en) | 2000-02-17 |
TW410220B (en) | 2000-11-01 |
PT938471E (pt) | 2002-05-31 |
BR9712525A (pt) | 1999-10-19 |
HK1021178A1 (en) | 2000-06-02 |
AU731737B2 (en) | 2001-04-05 |
EP0938471B1 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0000641A3 (en) | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them | |
IL129149A (en) | beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE | |
NZ304689A (en) | Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors | |
IL136300A0 (en) | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | |
IL138028A0 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use | |
HUP0000145A3 (en) | Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them | |
HUP9903687A3 (en) | Arylsulfonylamino carboxylic and hidroxamic acid derivatives and pharmaceutical compositions with metalloproteinase inhibitory activity containing them | |
ZA979238B (en) | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors. | |
HUP0103452A3 (en) | Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds | |
AU7294098A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
HUP0103344A3 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them | |
HUP0201680A2 (en) | Aromatic sulfone hydroxamic acid derivatives metalloprotease inhibitors and pharmaceutical compositions containing them | |
HUP0000657A3 (en) | N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them | |
HUP0100152A3 (en) | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity, pharmaceutical compositions containing them and their use | |
HUP0100186A3 (en) | Compounds as lactam metalloprotease inhibitors and pharmaceutical compositions containing them | |
HUP0002037A3 (en) | Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds | |
GB9401129D0 (en) | Hydroxamic acid derivatives as metalloproteinase inhibitors | |
HUP0002853A3 (en) | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them | |
HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
IL129420A0 (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors | |
HUP0003880A3 (en) | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same | |
HUP0203118A3 (en) | Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use | |
HRP970247A2 (en) | Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors | |
HUP9802645A3 (en) | New metalloproteinase inhibitors, process for producing them, and pharmaceutical compositions containing them | |
AU5034699A (en) | Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives andpeptide backbone modified derivatives thereof |